Sprint Bioscience AB (publ) today announced that it has entered into an agreement with Lilly TuneLab, a collaborative AI‑driven drug discovery platform created by Eli Lilly and Company (Lilly). By joining TuneLab, Sprint Bioscience aims to amplify and accelerate the development of the company’s research portfolio through access to advanced artificial intelligence (AI) and machine learning (ML) models.
Sprint Bioscience will leverage Lilly TuneLab to further strengthen its AI/ML capabilities. Through Tune lab, Sprint Bioscience will gain access to predictive drug discovery models trained on decades of Lilly’s proprietary research data. These models will complement Sprint Bioscience’s fragment‑based drug design platform and established methodology with advanced AI tools to enable more data‑driven decision‑making early in development. This is expected to increase the speed and precision of the company’s preclinical programs.
TuneLab provides models for areas such as safety, pharmacokinetics and early development decisions for both small molecules and biologics. Through a federated learning approach, participating companies can benefit from continuous improvements in the models without exposing their own data.
“We are very pleased to gain access to the Lilly TuneLab platform. The combination of our fragment‑based approach and advanced AI models provides strong opportunities to further enhance the efficiency and speed of our programs,” said Johan Emilsson, CEO of Sprint Bioscience.